Skip to main content
Konstantinos Arnaoutakis, MD, Oncology, Little Rock, AR

KonstantinosArnaoutakisMD

Oncology Little Rock, AR

Associate Professor, Internal Medicine, University of Arkansas COM

Dr. Arnaoutakis is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Arnaoutakis' full profile

Already have an account?

  • Office

    4301 W Markham St
    # 508
    Little Rock, AR 72205
    Phone+1 501-686-8000

Education & Training

  • St Elizabeth's Medical Center
    St Elizabeth's Medical CenterFellowship, Hematology and Medical Oncology, 2006 - 2009
  • Albany Medical Center
    Albany Medical CenterResidency, Internal Medicine, 2003 - 2006
  • University of Patras School of Medicine
    University of Patras School of MedicineClass of 1998

Certifications & Licensure

  • AR State Medical License
    AR State Medical License 2009 - 2026
  • MA State Medical License
    MA State Medical License 2006 - 2025
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2014

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • New UAMS Baptist Health Cancer Center Opens in North Little Rock
    New UAMS Baptist Health Cancer Center Opens in North Little RockAugust 30th, 2021
  • OncLive® Presents State of the Science Summit™ on Non-Small Cell Lung Cancer
    OncLive® Presents State of the Science Summit™ on Non-Small Cell Lung CancerJune 12th, 2019
  • Upfront Osimertinib Shows No Survival Advantage but Slows Brain Progression in EGFR-Mutant NSCLC Trial
    Upfront Osimertinib Shows No Survival Advantage but Slows Brain Progression in EGFR-Mutant NSCLC TrialMarch 12th, 2024

Professional Memberships